Hypomanic switch during vortioxetine treatment: a case report

Antidepressant-induced hypomanic/manic switch has been a controversial topic with regards to classification systems until the publication of the Diagnostic and Statistical Manual of Mental Disorders – Fifth Edition (DSM-5). Studies have indicated the effectiveness of vortioxetine in the treatment of depression since 2012; however, there are no data on the risk of hypomanic/manic switch associated with vortioxetine. This aim of this case report was to present a case of hypomania induced by vortioxetine in a patient who had received selective serotoin reuptake inhibitors and venlafaxine several times in the past for the treatment of recurrent depression

Extended-release trazodone in the treatment of major depressive disorder

Majör depresif bozukluk (MDB) sık görülen bir psikiyatrik bozukluktur. Tedavinin amacı belirtilerde remisyon ile günlük işlevlerin düzelmesidir ve antidepresanlar, majör depresif bir nöbetin (orta-şiddetli depresif nöbet) ilk sırada gelen tedavileridir. Bu makale uzatılmış salımlı trazodonun (TzCOAD) farmakolojik özelliklerini, MDB’deki klinik etkinliği ve güvenliğini incelemektedir. Uzman görüşü: Günde tek doz TzCOAD, hızlı salımlı trazodon (TzIR) ve diğer antidepresanlara benzer bir etkinlik ve artmış tolerabilite sağlayabilir. (Anadolu Psikiyatri Derg 2019; 20(5):453-459)Major depressive disorder is a common psychiatric disorder. the aim of the treatment is to improve daily functions with remissions in symptoms, and antidepressants are the first-line treatments for a major depressive episode (moderate-severe depressive episode). in this paper, the pharmacological properties, clinical efficacy and safety of extended-release trazodone (TzCOAD) are studied. Expert opinion: A single daily dose of TzCOAD may provide similar efficacy and increased tolerability to immediate-release trazodone (TzIR) and other antidepressants. (Anatolian Journal of Psychiatry 2019; 20(5):453-459